BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 26231950)

  • 1. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Sudilovsky D; Hylton NM
    AJR Am J Roentgenol; 2002 Nov; 179(5):1193-9. PubMed ID: 12388497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
    Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
    Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim TH; Kang DK; Yim H; Jung YS; Kim KS; Kang SY
    J Comput Assist Tomogr; 2012; 36(2):200-6. PubMed ID: 22446360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
    Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
    Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [No Abstract]   [Full Text] [Related]  

  • 15. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients.
    Murata Y; Ogawa Y; Yoshida S; Kubota K; Itoh S; Fukumoto M; Nishioka A; Moriki T; Maeda H; Tanaka Y
    Oncol Rep; 2004 Dec; 12(6):1257-62. PubMed ID: 15547747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.
    Furman-Haran E; Nissan N; Ricart-Selma V; Martinez-Rubio C; Degani H; Camps-Herrero J
    J Magn Reson Imaging; 2018 Apr; 47(4):1080-1090. PubMed ID: 28901594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.